Asia CDMO news Update December 2025

April 7, 2026

CDMO Capsules: Asia’s Strategic Ascendance in Pharmaceutical Manufacturing

The global pharmaceutical landscape is currently witnessing a tectonic shift toward the East. As we close out December 2025, the Asia-Pacific (APAC) region has not just maintained its position but has solidified its role as the primary engine for the Contract Development and Manufacturing Organization (CDMO) sector. Asia CDMO News shows Asian CDMOs redefining top-tier partnerships through investment, ADC innovation, and regulatory expertise.
Asia CDMO News covers major deals, innovations, and CDMO expansions across South Korea, China, and ASEAN.

The $117 Billion Horizon: Market Dynamics in late 2025

The year 2025 has been a watershed moment for the Asian manufacturing market. Recent industry data indicates that the Asia-Pacific CDMO market is currently valued at approximately $77.76 billion and is on a trajectory to hit $117.46 billion by 2030, growing at a consistent CAGR of 8.60% (Mordor Intelligence, 2025).

This growth is no longer merely about “low-cost labor.” Instead, it is fueled by:

Infrastructure Sophistication: The transition from traditional small-molecule manufacturing to complex biologics, peptides, and cell/gene therapy (CGT).
Regulatory Alignment: Increased adherence to international cGMP standards, making Asian facilities the preferred choice for 17 of the world’s top 20 pharmaceutical companies.
Injectable Demand: A surge in demand for sterile injectables, particularly driven by the oncology sector and the global rise in diabetes treatments like GLP-1 agonists (GlobeNewswire, 2025).

Samsung Biologics: The World’s Largest Capacity Powerhouse

In the final weeks of 2025, Samsung Biologics (https://samsungbiologics.com) has dominated the news cycle with a series of high-value contract wins and a major corporate restructuring.

A Pure-Play CDMO Pivot

On November 3, 2025, the company officially completed the spin-off of its investment and subsidiary management business unit, establishing Samsung Epis Holdings. This strategic move allows Samsung Biologics to operate as a “pure-play CDMO” (Goodwin Law, 2025). By separating its manufacturing services from its product development wing, the company aims to eliminate any perceived conflicts of interest and focus entirely on its three strategic pillars: capacity expansion, service diversification, and global footprint strengthening.

Breaking Contract Records

The financial momentum is staggering. As of December 2025, Samsung Biologics has surpassed $2.2 billion in contract orders for the year (MedPath, 2025). This includes a landmark $1.29 billion deal with a U.S.-based pharmaceutical company—one of the largest single-client contracts in the company’s history (Korea JoongAng Daily, 2025).

Capacity Milestone: With the operational launch of Plant 5 in April 2025, the company’s total biomanufacturing capacity has reached 784,000 liters, establishing the world’s largest production volume in a single site (MedPath, 2025).
Next-Gen Focus: The company is now aggressively targeting the ADC market, with a dedicated facility designed to meet the soaring demand for targeted cancer therapies.

WuXi Biologics: Navigating Geopolitical Waters

While capacity is the focus in South Korea, WuXi Biologics (https://www.wuxibiologics.com) is currently navigating a complex regulatory environment in the United States. In December 2025, the U.S. Congress officially passed the BIOSECURE Act as part of the National Defense Authorization Act (NDAA) (pharmaphorum, 2025).

The BIOSECURE Act Impact

The legislation, passed on December 17, 2025, designates certain Chinese entities as “biotechnology companies of concern,” potentially barring them from federal contracts. However, the industry has breathed a sigh of relief as the final version includes a five-year grandfather clause for existing contracts (Greenberg Traurig, 2025). This provides a critical buffer for global pharma partners to manage their supply chains without immediate disruption.

Sustainability Leadership: Despite geopolitical headwinds, WuXi continues to lead in ESG. This month, the company achieved “double A” ratings from the CDP for both Climate Change and Water Security, highlighting its commitment to Net-Zero emissions by 2050 (WuXi Biologics, 2025).

Lotte Biologics: The ADC Specialist

Lotte Biologics (https://www.lottebiologics.com) is rapidly establishing itself as a specialized leader in the ADC CDMO market. Throughout the final quarter of 2025, the company has focused on its “Dual-Hub Strategy,” bridging its Syracuse, New York campus with its emerging Songdo Bio Campus in South Korea.

The Syracuse Milestone

In late 2025, Lotte announced the successful start of its $100 million ADC manufacturing facility in Syracuse. This site recently secured its first major manufacturing agreement with an Asia-based biotech company for a clinical-stage ADC candidate (PR Newswire, 2025).

Technological Innovation: At the recent Bio Japan 2025 forum, CEO James Park showcased the company’s proprietary SoluFlex Link technology, designed to optimize the conjugation process for next-generation cancer therapies (KED Global, 2025).
Songdo Expansion: Construction is currently ahead of schedule for the first plant of the Songdo Bio Campus, which is expected to be operational by 2027, adding 360,000 liters of capacity (MK, 2025).

Lonza and Regional Trends: Peptides and Small Molecules

While biologics often steal the spotlight, the broader Asian CDMO market is seeing significant movement in specialized small molecules and oral dosage forms.

Lonza’s Regional Strategy

Lonza (https://www.lonza.com) has recently expanded its hard gelatin capsule (HGC) manufacturing lines in Suzhou, China, and Rewari, India (PharmaSource, 2025). This expansion is part of a broader “Capsules and Health Ingredients” (CHI) strategy to meet the rising regional demand for nutraceuticals and complex oral pharmaceuticals.

Portfolio Shift: At the end of 2025, Lonza’s leadership confirmed a plan to potentially exit certain non-core CHI businesses to concentrate further on its core CDMO biologics and advanced synthesis platforms (Pharmaceutical Technology, 2025).

The Peptide Boom

Asia has also become the world’s leading hub for peptide CDMOs. As of December 2025, China accounts for 28% of the global peptide manufacturing base, followed by India at 12% (Global Growth Insights, 2025). Companies like Aurigene Pharmaceutical Services in India and Chengdu Shengnuo in China are leading the charge in large-scale Solid Phase Peptide Synthesis (SPPS).

Looking Ahead: What to Expect in 2026

As we move into 2026, the Asian CDMO sector is poised to face a “New Normal.” The focus will shift from purely scaling volume to integrated service models. Pharmaceutical clients are increasingly looking for “one-stop shop” partners that can handle everything from early-stage R&D to final sterile fill-finish (Biospectrum Asia, 2025).

The fundamental drivers—the rise in chronic diseases, the personalized medicine boom, and the need for scalable, high-tech manufacturing—ensure that Asia will remain the heart of the CDMO world for the foreseeable future.

Would you like me to prepare a specialized deep-dive report on the upcoming 2026 facility launches in Singapore and India?